EUVIMEDEUVIMED entdecken
Crossref

Tramadol and Its Influence on Platelet Function — An Ex Vivo Study

Philipp Zoidl iD, Helmar Bornemann-Cimenti, Michael Eichinger, Michael Eichlseder, Lioba Heuschneider, Nikolaus Schreiber, Paul Zajic, Gudrun Rumpold-Seitinger, Florian Prüller, Gabriel Honnef

Hämostaseologie · 12.02.2026

DOI: 10.1055/a-2780-3616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 12.02.2026. Verfasst von Philipp Zoidl und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria. Die Arbeit nennt 15 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tramadol, a weak μ-opioid receptor agonist and a widely used analgesic, also inhibits serotonin and norepinephrine reuptake, which could potentially influence platelet function. While the bleeding risk of selective serotonin reuptake inhibitors is well documented, the impact of tramadol on platelet aggregation, despite its widespread use, remains underexplored. Therefore, this study aims to elucidate tramadol’s effect on platelet function. This single-center laboratory study involved healthy volunteers at the Medical University of Graz, Austria. Platelet function was assessed using light transmission aggregometry following the addition of tramadol in increasing concentrations (0, 500, 1500, 4500, and 9000 ng/mL) to blood samples. Baseline and post-tramadol-addition platelet aggregation was measured using adenosine diphosphate-induced (ADP), ristocetin-induced, and thrombin-receptor activating peptide-induced (TRAM) aggregation. Statistical analysis employed the Friedman test. Seven healthy volunteers could be included in the final analysis. Platelet aggregation was assessed after ex vivo addition of tramadol (500–9000 ng/mL). No significant differences in aggregation percentages were observed between tramadol concentrations and baseline inducing activation with ADP, ristocetin, or TRAP. These findings suggest that tramadol, at therapeutic and supratherapeutic concentrations, does not significantly impair platelet function in most individuals. This supports the general safety profile of tramadol regarding platelet aggregation. Tramadol appears safe concerning platelet function. Further research with larger cohorts is warranted to confirm these results and investigate potential interindividual variability in response to tramadol.

Autor:innen und Institutionen

  • Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria.
  • Clinical Institute for Medical and Chemical Laboratory Diagnostics (KIMCL), Medizinische Universität Graz, Graz, Austria.

ORCID-Profile: Philipp Zoidl

Zitieren

APA

Zoidl, P., Bornemann-Cimenti, H., Eichinger, M., Eichlseder, M., Heuschneider, L., Schreiber, N., Zajic, P., Rumpold-Seitinger, G., Prüller, F., & Honnef, G. (2026). Tramadol and Its Influence on Platelet Function — An Ex Vivo Study. Hämostaseologie. https://doi.org/10.1055/a-2780-3616

Vancouver

Zoidl P, Bornemann-Cimenti H, Eichinger M, Eichlseder M, Heuschneider L, Schreiber N, et al. Tramadol and Its Influence on Platelet Function — An Ex Vivo Study. Hämostaseologie. 2026. doi:10.1055/a-2780-3616

BibTeX
@article{Zoidl2026,
  author = {Zoidl, Philipp and Bornemann-Cimenti, Helmar and Eichinger, Michael and Eichlseder, Michael and Heuschneider, Lioba and Schreiber, Nikolaus and Zajic, Paul and Rumpold-Seitinger, Gudrun and Prüller, Florian and Honnef, Gabriel},
  title = {Tramadol and Its Influence on Platelet Function — An Ex Vivo Study},
  journal = {Hämostaseologie},
  year = {2026},
  doi = {10.1055/a-2780-3616}
}
Kostenlos starten →